Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Masimo Corporation has entered into an Agreement and Plan of Merger to be acquired by Danaher Corporation. Danaher will acquire Masimo through a merger in which Mobius Merger Sub, Inc. merges with and into Masimo, with Masimo surviving as a wholly owned subsidiary of Danaher.
Under the merger terms, each share of Masimo common stock outstanding immediately prior to the effective time (excluding shares owned by Danaher, Merger Sub, Masimo, and any excluded dissenting shares) will be converted into the right to receive $180.00 in cash per share, without interest. The proxy materials also describe a Voting and Support Agreement with Politan Capital Management LP, representing approximately 8.77% of outstanding voting power.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026